ERIS — Eris Lifesciences Cashflow Statement
0.000.00%
Last trade - 00:00- IN₹202.41bn
- IN₹231.92bn
- IN₹20.09bn
Annual cashflow statement for Eris Lifesciences, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IAS | IAS | IAS | IAS | IAS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 3,314 | 3,945 | 4,422 | 4,046 | 4,312 |
| Depreciation | |||||
| Non-Cash Items | -60.2 | 10.9 | -155 | 228 | 717 |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -1,045 | -632 | -1,132 | -2,453 | -1,725 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | 2,711 | 3,754 | 3,783 | 2,992 | 5,130 |
| Capital Expenditures | -1,513 | -258 | -1,210 | -8,414 | -1,292 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 2,746 | -2,976 | -1,986 | -1,407 | -17,254 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 1,233 | -3,234 | -3,196 | -9,821 | -18,545 |
| Financing Cash Flow Items | -35 | -17.8 | -33.2 | -234 | -876 |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -3,346 | -824 | -447 | 6,880 | 13,798 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 598 | -304 | 140 | 51.5 | 382 |